Rizatriptan Benzoate
Product Images NDC 53002-3713

5 FDA label images from Rpk Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 53002-3713). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl530023713)

Label Image (Lbl530023713)
Rizatriptan Benzoate 10 mg tablets packaging label from RPK Pharmaceuticals, Inc. The label includes drug details, patient information sheet instructions, and dispensing information for a 1-pack (15 tablets). It displays barcode, lot number, expiration date, and billing codes. The design is in black and white with text organized in blocks.*
FDA Label Image

Rizatriptan-fig-1 (Rizatriptan Fig 1)

Rizatriptan-fig-1 (Rizatriptan Fig 1)
A line graph depicting the estimated probability of response over time (hours post-dose) for placebo, Rizatriptan Benzoate 5 mg, and Rizatriptan Benzoate 10 mg. The x-axis indicates hours post-dose up to 2 hours, and the y-axis shows the estimated probability of response from 0% to 100%. Response probability increases with dose and time.*
FDA Label Image

Rizatriptan-fig-2 (Rizatriptan Fig 2)

Rizatriptan-fig-2 (Rizatriptan Fig 2)
A line graph showing the estimated probability of medication or rescue over 24 hours post-dose for Rizatriptan Benzoate 5 mg, Rizatriptan Benzoate 10 mg, and placebo groups. The graph illustrates higher probabilities for Rizatriptan Benzoate doses compared to placebo over time.*
FDA Label Image

Rizatriptan-fig-5 (Rizatriptan Fig 5)

Rizatriptan-fig-5 (Rizatriptan Fig 5)
A line graph comparing the percentage response over time (hours post Stage 2 dose) between Rizatriptan Benzoate and placebo. The x-axis represents hours post dose, and the y-axis shows response percentage with error bars indicating confidence intervals. Rizatriptan Benzoate demonstrates a higher percentage response than placebo over the 0.5 to 2 hours measured.*
FDA Label Image

Rizatriptan-structure (Rizatriptan Structure)

Rizatriptan-structure (Rizatriptan Structure)
Chemical structure of rizatriptan benzoate showing the molecular arrangement of the rizatriptan moiety linked to a benzoate group. The diagram depicts aromatic rings and functional groups typical of this compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.